FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns a therapeutic agent for at least one disease specified in a group consisting of thyroid cancer, multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid cancer, papillary medullary thyroid cancer, sporadic medullary thyroid cancer, Hirschsprung's disease, pheochromocytoma, parathyroid hyperplasia and gastrointestinal mucosal neuroma, containing: 4-(3-Chlor-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or its analogues, a pharmaceutical composition containing said agent, a method of treating said diseases, using 4-(3-Chlor-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or its analogues for treating said diseases.
EFFECT: developing the new therapeutic agent.
11 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER THERAPEUTIC AGENT | 2012 |
|
RU2580609C2 |
| CRYSTAL FORM OF 4-(3-CHLORINE-4-(CYCLOPROPYLAMINOCARBONYL)AMINOPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE SALT OR ITS SOLVATE AND METHODS FOR ITS PRODUCING | 2004 |
|
RU2328489C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
| RET INHIBITOR FOR USE IN THE TREATMENT OF CANCER WITH RET ALTERATION | 2019 |
|
RU2800951C2 |
| SET OF SEQUENCES OF OLIGONUCLEOTIDES FOR DIAGNOSTICS OF GERMINAL MUTATIONS IN GENE RET, ASSOCIATED WITH GENETIC PREDISPOSITION TO CANCER OF THYROID | 2013 |
|
RU2524433C1 |
| ANTICANCER AGENT INVOLVING COMBINATIONS OF KINASE INHIBITORY COMPOUNDS | 2011 |
|
RU2560683C2 |
| PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND ITS USE | 2018 |
|
RU2789405C2 |
| RET INHIBITOR | 2013 |
|
RU2648818C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING QUINOLINE DERIVATIVE | 2010 |
|
RU2548673C2 |
| COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARING THE COMPOUNDS AND THEIR USE AS ATR KINASE INHIBITORS | 2019 |
|
RU2806857C2 |
